Back to results
US 8,946,252 B2Granted
Methods of treating traveler's diarrhea and hepatic encephalopathy
AssigneeSalix Pharmaceuticals, Inc.
InventorsWilliam Forbes, Enoch Bortey
Life of this patent
Estimating the term…
Abstract
Treatment of traveler's diarrhea using in subjects having hepatic encephalopathy using gastrointestinal specific antibiotics is disclosed. One example of a gastrointestinal specific antibiotic is rifaximin.
Claims27
A method of reducing the risk of overt hepatic encephalopathy (HE) recurrence in a subject comprising:
- identifying a subject having Traveler's Diarrhea (TD) that also has hepatic insufficiency;
- determining if the subject's Child-Pugh score is Child-Pugh Class C or if the subject's model end stage liver disease (MELD) score is 25 or greater;
- and
- administering between 1000 and 1200 mg of rifaximin daily and cautiously to the subject if his or her Child-Pugh score is Child-Pugh Class C or if his or her MELD score is 25 or greater.
1 more element
A method to reduce the risk of overt hepatic encephalopathy (HE) recurrence in a subject suffering from Traveler's Diarrhea (TD), comprising:
- identifying a subject that has had overt HE and also TD;
- determining the severity of the subject's HE;
- administering between 1000 and 1200 mg of rifaximin daily and cautiously for TD to the subject if the HE is severe.
Dependencies are inferred from the claim text.